Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Focalin · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| Focalin XR | DRUG | - |
Inclusion Criteria: * DSM-IV diagnosis of ADHD * Males and females aged 6-12 Exclusion Criteria: * Inability of understand or follow instructions * Is pregnant * Diagnosis of tic disorder * History of seizure disorder
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | SUPN | 1 | PHASE3 | SPN-812 |
Focalin is used for the treatment of attention deficit hyperactivity disorder (ADHD). It is a small molecule drug being developed by Novartis AG for this psychiatric condition. The drug is currently in Phase 3 clinical development, meaning it is still investigational and has not yet been approved by regulatory authorities.
Focalin is being developed by Novartis AG, a pharmaceutical company traded on the stock exchange under the ticker symbol NVS. The company is conducting clinical trials to evaluate the safety and efficacy of Focalin in patients with ADHD.
Focalin is currently in Phase 3 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval. Two Phase 3 clinical trials have been completed to evaluate its safety and efficacy in children with ADHD.
Focalin has been studied in two completed Phase 3 clinical trials: NCT00141050 and NCT00141063. Both trials were conducted in the United States and enrolled 90 children each, for a total of 180 participants. The trials were randomized, double-blind, and uncontrolled, and included children aged 6 years and older with ADHD.
Focalin is the brand name for dexmethylphenidate, a medication used to treat ADHD. The clinical trials for Focalin, identified as NCT00141050 and NCT00141063, were titled 'Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD,' confirming that Focalin and dexmethylphenidate refer to the same drug.